Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Medipost
Seongnam-si, South Korea
A
- Employees
-
Key takeaway
MEDIPOST is at the forefront of regenerative medicine, having successfully commercialized CARTISTEM®, the world's first regulatory-approved allogeneic stem cell product for treating degenerative osteoarthritis. The company is also advancing the field with ongoing clinical trials for its PNEUMOSTEM® product, aimed at preventing bronchopulmonary dysplasia.
Reference
Service
Development Status - MEDIPOST
MEDIPOST stem cell treatment research and development status page. MEDIPOST succeeded in the commercialization of Cartistem, an allogeneic cord blood-derived mesenchymal stem cell treatment.
ReMedium Korea
Seoul, South Korea
A
11-50 Employees
-
Key takeaway
The company, ReMedium, emphasizes its commitment to innovation and scientific excellence in the development of a diverse range of aesthetic products, including facial injectables and body contouring solutions. Their research and development efforts focus on groundbreaking advancements, ensuring that their offerings are both aesthetically appealing and scientifically credible.
Reference
Core business
Remedium - Remedium Korea
ReMedium, We Manufacture the best Korean Fillers, Threads and other medical devices.ReMedium products are made from Korea and have completed the clinical trials at the Seoul National University Hospital.
Clecell co.ltd
Seongnam-si, South Korea
A
11-50 Employees
2016
Key takeaway
The company is pioneering advancements in regenerative medicine through its innovative bioprinting and tissue engineering technologies, which facilitate the creation of artificial human tissues and organoids. Their high-throughput bioprinting platform is particularly focused on developing personalized in vitro cancer tissues for effective testing of treatment methods.
Reference
Core business
CLECELL | Biotechnology company | South Korea
CLECELL is trailblazing the field of personalized and regenerative medicine with our revolutionary bioprinting and tissue engineering technology.
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Femtobiomed
Seongnam-si, South Korea
A
11-50 Employees
2011
Key takeaway
FEMTOBIOMED.inc focuses on advancing targeted gene delivery through multiplexed cell therapeutics, highlighting its innovative approach in the field of regenerative medicine.
Reference
Core business
FEMTOBIOMED
Celltrion
Incheon, South Korea
A
501-1000 Employees
2002
Key takeaway
Celltrion is a global biopharmaceutical company that emphasizes its strong R&D capabilities and commitment to enhancing patient health through innovative biologics. They have established a direct sales network in major markets and have a history of regulatory compliance, which supports their goal of improving access to high-quality biopharmaceuticals.
Reference
Product
Technology
ProCell Therapeutics
Seoul, South Korea
A
1-10 Employees
2005
Key takeaway
ProCell is focused on becoming a leader in the biopharmaceutical sector, which aligns with the advancements in regenerative medicine. Their expertise in drug development and innovative technologies positions them well in this field.
Reference
Core business
프로셀테라퓨틱스
MITT,MTD,거대분자세포내전송기술보유,신약개발,바이오벤처기업,피투스킨,성장인자원료,기능성화장품,OEM,ODM
Spidercore Inc.
Daejeon, South Korea
A
1-10 Employees
2020
Key takeaway
Spidercore is focused on enhancing gene therapy through its AI engine, S.Core, which analyzes the properties of nucleotides to discover reliable gene therapies. Their platform aims to improve decision-making in biomedical care, ultimately enhancing patient outcomes and making advanced treatments more accessible.
Reference
Core business
Spidercore Inc.
Cellumed
Seoul, South Korea
A
251-500 Employees
1997
Key takeaway
Cellumed is actively engaged in research and development of tissue engineering products and has a human tissue bank that processes and distributes high-quality grafts. Their focus on innovative therapies, including the development of key enzyme proteins for mRNA production, aligns with advancements in regenerative medicine.
Reference
Core business
Cellumed
Genuv
Seoul, South Korea
A
11-50 Employees
2016
Key takeaway
Genuv is focused on developing innovative treatments for neurodegenerative diseases through the stimulation of innate neural stem cells and restoration of CNS function. Their approach goes beyond traditional methods by targeting immune cells and promoting neuroprotection and neurogenesis.
Reference
Core business
Genuv
Biopharmaceutical company. 신약발굴 플랫폼 기술을 바탕으로 퇴행성 뇌질환, 면역질환, 암질환 등, 난치성 질환분야에서 치료제를 개발하는 연구 중심 신약 개발 기업.
Onegene Biotechnology
Seongnam-si, South Korea
A
- Employees
2016
Key takeaway
Onegene Biotechnology is focused on advancing research and development in the field of multi-target drug development, which may contribute to breakthroughs in regenerative medicine. Their innovative approach involves dissecting disease microenvironments and developing multi-specific drugs, positioning them at the forefront of treating complex diseases.
Reference
Core business
ONEGENE BIOTECHNOLOGY
Technologies which have been searched by others and may be interesting for you:
When exploring the regenerative medicine industry in South Korea, it is crucial to understand the regulatory landscape, as the country has established specific guidelines for the development and commercialization of cell therapies and tissue engineering. The Ministry of Food and Drug Safety (MFDS) oversees these regulations, which may differ from those in other regions. Challenges such as ethical considerations, particularly regarding stem cell research, and the need for rigorous clinical trials must also be acknowledged. Opportunities abound due to South Korea's robust research infrastructure, significant government investment, and a strong focus on biotechnology, making it an attractive hub for innovation. Furthermore, the competitive landscape includes established firms and startups, fostering a dynamic environment for partnerships and collaborations. Environmental concerns related to biowaste management and the sustainability of sourcing biomaterials are increasingly important in this sector. Finally, the global market relevance of South Korea's regenerative medicine industry is on the rise, with local companies expanding their reach through international collaborations and participation in global clinical trials, thereby enhancing their visibility and impact in the worldwide market.
Some interesting numbers and facts about your company results for Regenerative Medicine
| Country with most fitting companies | South Korea |
| Amount of fitting manufacturers | 19 |
| Amount of suitable service providers | 6 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1997 |
| Youngest suiting company | 2020 |
Some interesting questions that has been asked about the results you have just received for Regenerative Medicine
What are related technologies to Regenerative Medicine?
Based on our calculations related technologies to Regenerative Medicine are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Regenerative Medicine?
The most represented industries which are working in Regenerative Medicine are Biotechnology, Medical, Other, Pharmaceuticals, IT, Software and Services
How does ensun find these Regenerative Medicine Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.